SCHOLARLY PUBLICATION

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

📖 The Lancet Oncology → 📅 2015-04-12 🔗 DOI: 10.1016/s1470-2045(15)70127-0

View Journal Profile → View Official Paper ↗

📄 Abstract

The abstract has not yet been added. Use the official source link for the complete publication record.

ℹ️ Publication Details

Journal: The Lancet Oncology
Published: 2015-04-12
DOI: 10.1016/s1470-2045(15)70127-0
OpenAlex: W2121847974
Access: Via publisher

📋 Cite This Paper

Josep M. Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Lordick Obermannova, Gyorgy Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David Craig Portnoy, Eric Van Cutsem, Axel F. Grothey, Jana Prausová, Pilar García Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah (2015). Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)70127-0

📄 Abstract

🔬 Related Research Papers

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study

The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016

Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study